Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beijing Double-crane Pharmaceutical Acquires Shenzhou Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

Guangdong Shenzhou Pharmaceutical, one of the few companies producing soft packaging for transfusion in South China, faces huge debts after establishing four advanced production lines for PVC soft packaging. Beijing Double-crane Pharmaceutical will acquire 90 percent stake of the cash-strapped company for a token 1 yuan; the purchase will double its soft packaging production capacity and improve current processes and bottom line. The acquisition of high-tech hardware and manufacturing facilities will strengthen Double-crane's position in South China and improve its nationwide production network. Double-crane will incorporate Shenzhou's management, production, purchase and allocation processes into its management model for maximum optimization. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel